Immune Pharmaceuticals raises $11.7m on Nasdaq
A patent infringement suit was filed by Wyeth, now owned by Pfizer.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) could be required to pay hundreds of millions of dollars in compensation to Wyeth (NYSE: WYE) and Pfizer Inc. (NYSE: PFE; LSE: PFZ) after the jury in the US District Court for the District of New Jersey ruled that the US patent of Protonix held by Swiss Nycomed Gmbh’s is valid.
Nycomed licensed Protonix to Wyeth. Wyeth was bought by Pfizer at the end of 2009. Nycomed and Wyeth filed the patent infringement case against Teva in May 2004.
Protonix is a treatment for Gastro Esophageal Reflex Disease (GERD). Teva made an at-risk launch of generic Protonix in December 2007. US sales of Protonix, a blockbuster drug, fell 58% in the year following the launch of the generic version, and Wyeth's revenue took a severe hit, since Protonix is an important source of income.
India's Sun Pharmaceutical Industries Ltd. (BSE: 524715) also launched a generic version of Protonix.
While the jury ruled that the patent was valid, there were other defense claims by Teva, which were not ruled on. If a judge sides with Teva on these issues, it would also invalidate the patent.
Harel Finance analyst Steven Tepper said, "Teva took a risk on Protonix, and may have to pay $1-3 billion to Wyeth/Pfizer. The US jury found that Teva infringed on the Protonix patent, and the judge's decision will be in a few weeks. Teva claims that this is not the final word, and that the judge has to decide whether the patent is valid and there is no duplication of patents. We believe that the damage to Teva will reach $1 billion, with a small chance of reaching $3 billion, if the court rules that Pfizer is entitled to three-fold compensation."
UBS analyst Mark Goodman estimates the maximum possible damage to Teva at $450 million. He said, "We don’t rule out a legal settlement. We'll wait for things to clear, since we don’t yet know if Teva has completely lost."
Goodman gives Teva a "Buy" recommendation with a target price of $74.
Teva's share closed at $61.54 on Nasdaq on Friday. The share price fell 1.9% in early trading on the TASE today to NIS 227.60.
Published by Globes [online], Israel business news - www.globes-online.com - on April 25, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010
You comment was recieved and soon will be published.
Load more comments
The money raised will fund a Phase II trial of ulcerative colitis drug bertilmumab.
XTL Biopharma files to raise $40m on Nasdaq
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.